Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis makes competing bid for Zentiva

Sanofi-aventis has announced that it intends to make a bid of $1.7bn for the Czech generic drug manufacturer, Zentiva
Sanofi-aventis has announced that it intends to make a bid of $1.7bn for the Czech generic drug manufacturer, Zentiva, outbidding an earlier offer from Czech financial group PPF.

Paris-based sanofi-aventis already holds a 24.9 per cent share in Zentiva while PPF, together with Italian insurer Generali, owns 19.2 per cent. The offer from sanofi-avensis is 10.5 per cent higher than the initial bid from the Czech financial house.

The acquisition of Zentiva would give the French pharmaceutical company more than 180 generic medicines, an area of the market growing at twice the rate of patent-protected products.

Zentiva is a market leader in the Czech Republic, Turkey, Romania and Slovakia, with a growing presence in Poland, Russia, Bulgaria, the Ukraine and the Baltic countries. Sanofi-aventis is already established in many of these markets and says that acquiring control of the generics manufacturer "carries a strong strategic rationale."

18th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics